合并创伤性颅内血肿与脑静脉窦血栓形成患者的抗凝策略:一项观察性队列研究
单中心观察性队列纳入2006至2020年间1039例成人TBI患者中32例合并颅内血肿与创伤后脑静脉窦血栓形成者,按机构方案使用低分子肝素或肝素输注抗凝。结果显示无出血并发症,3例(9.4%)发生血栓并发症;作者认为约50%治疗水平的低分子肝素有效,但需前瞻性试验确认。
要点
- 32例合并颅内血肿与创伤后脑静脉窦血栓形成的TBI患者接受肝素输注(n=8)或低分子肝素(n=24)抗凝。
- 无出血并发症,即使低分子肝素剂量≥50%治疗水平亦无出血并发症。
- 血栓并发症3例(9.4%),包括血栓进展2例和静脉梗死1例。
核心结论
- 作者认为,在其回顾性数据集中,约50%治疗水平的低分子肝素对TBI相关创伤后脑静脉窦血栓形成有效,且无血肿扩大风险。
- 作者指出需前瞻性试验确认这些结果。
研究设计与样本
- 单中心观察性队列研究,纳入2006至2020年间收治的1039例TBI患者中32例符合纳入标准的成人TBI合并颅内血肿与创伤后脑静脉窦血栓形成患者。
- 所有创伤后脑静脉窦血栓形成均按机构方案使用低分子肝素或肝素输注治疗。
主要发现
- 从受伤至创伤后脑静脉窦血栓形成诊断的中位时间为24小时。
- 抗凝治疗在创伤后脑静脉窦血栓形成诊断后中位9小时启动。
- 患者接受肝素输注(n=8)或低分子肝素(n=24),低分子肝素剂量范围为治疗水平的28%至72%。
- 无出血并发症,即使接受低分子肝素剂量≥50%治疗水平的患者亦无出血并发症。
- 血栓并发症发生于3例患者(9.4%),包括血栓进展2例和静脉梗死1例;发生血栓并发症的患者与未发生者的差异在于诊断后启动抗凝延迟17小时或初始低分子肝素剂量为治疗水平的28%。
局限性
- 原文在结论中写明需前瞻性试验确认这些结果。
- 原文在结论中称其数据为回顾性数据集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Post-traumatic cerebral venous sinus thrombosis (ptCVT) is a rare but serious complication of traumatic brain injury (TBI). Managing ptCVT is challenging due to the concurrent risk of traumatic intracranial hematoma (ICH) expansion. Limited data exists on the safety and efficacy of anticoagulation therapy (ACT) in these cases. METHODS: This single-center observational cohort study included adult TBI patients with concurrent ICH and ptCVT. Low-molecular-weight heparin (LMWH) or heparin infusion was used to treat all ptCVTs based on institutional protocols. The outcomes of interest were hemorrhagic and thrombotic complications. RESULTS: Out of 1,039 TBI-patients admitted between 2006 and 2020, 32 met the inclusion criteria. The median time from injury to ptCVT diagnosis was 24 h. ACT was initiated at a median of 9 h after ptCVT diagnosis. Patients were administered either heparin infusion (n = 8) or LMWH at dosages ranging from 28 to 72% of the therapeutic level (n = 24). There were no hemorrhagic complications, even in patients receiving LMWH at ≥ 50% of the therapeutic dose. Thrombotic complications occurred in 3 patients (9.4%) - two cases of thrombus progression and one venous infarct. The patients who developed thrombotic complications differed from those who did not by having a 17-h delay in ACT initiation after diagnosis or by receiving an initial LMWH dose at 28% of the therapeutic level. CONCLUSION: LMWH at approximately 50% of the therapeutic level was effective for managing ptCVT associated with TBI in our retrospective dataset, with no risk of hematoma expansion. Prospective trials are warranted to confirm these results.
引用
- Antonsson J, Tatter C, Ågren A, et al. Anticoagulation strategies in patients with coexisting traumatic intracranial hematomas and cerebral venous sinus thrombosis: an observational cohort study. Acta Neurochir (Wien). 2024. PMID: 39331162. doi:10.1007/s00701-024-06287-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。